NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP reduced its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 95.7% in the 2nd quarter, Holdings Channel.com reports. The firm owned 218,749 shares of the company’s stock after selling 4,897,069 shares during the period. Wellington Management Group LLP’s holdings in NewAmsterdam Pharma were worth $7,413,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Wells Fargo & Company MN lifted its holdings in NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after buying an additional 300 shares during the last quarter. KBC Group NV purchased a new stake in NewAmsterdam Pharma during the first quarter worth approximately $37,000. Navalign LLC acquired a new position in NewAmsterdam Pharma in the fourth quarter valued at approximately $46,000. AdvisorNet Financial Inc purchased a new position in NewAmsterdam Pharma in the first quarter valued at approximately $82,000. Finally, Empowered Funds LLC acquired a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at $85,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Up 0.9%

Shares of NewAmsterdam Pharma stock opened at $25.63 on Wednesday. The firm has a market cap of $3.06 billion, a price-to-earnings ratio of -11.87 and a beta of 0.09. NewAmsterdam Pharma Company N.V. has a 52-week low of $23.05 and a 52-week high of $42.21. The company’s 50-day simple moving average is $29.34 and its 200-day simple moving average is $31.45.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $2.83 million. Equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current year.

Insider Buying and Selling

In related news, CAO Louise Kooij sold 105,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $30.34, for a total value of $3,185,700.00. Following the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at $738,870.02. The trade was a 81.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Johannes Kastelein sold 125,000 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $26.91, for a total value of $3,363,750.00. Following the completion of the transaction, the insider owned 69,302 shares of the company’s stock, valued at $1,864,916.82. The trade was a 64.33% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 270,000 shares of company stock valued at $7,757,450. Company insiders own 12.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. HC Wainwright reiterated a “buy” rating and set a $52.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. BMO Capital Markets began coverage on shares of NewAmsterdam Pharma in a report on Monday, July 20th. They issued an “outperform” rating and a $58.00 target price for the company. Finally, Royal Bank Of Canada decreased their target price on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $49.73.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.